Pricing & Access· July 18, 2026 · 18 min read
Sarclisa Escena SC access: CirCLIQ on-body injector, trial data, and billing
By Ran Chen#Oncology#FDA Approval#Specialty Pharmacy
Topic
J-Code
HCPCS Level II J-codes for provider-administered drugs, code assignment timing, interim billing, and new drug coding cycles.
Approvals· July 16, 2026 · 19 min read
Revtorpyk (gedatolisib) coverage: breast cancer approval and billing
By Ran Chen#Oncology#Breast Cancer#FDA Approval
Pricing & Access· July 14, 2026 · 18 min read
Generalized Myasthenia Gravis (gMG) Access and Dosing Landscape
By Ran Chen#Rare Disease#Payer Policy#HCPCS Coding
Pricing & Access· July 14, 2026 · 20 min read
PNH Access Landscape: C5 Blockers, Orals, and the Biosimilar Cliff
By Ran Chen#Rare Disease#Payer Policy#HCPCS Coding
Pricing & Access· June 24, 2026 · 26 min read
Roche Genentech Portfolio Dossier: Subcutaneous Biologic Transitions
By Ran Chen#Purple Book#Biosimilars#J-Code
Pricing & Access· June 21, 2026 · 6 min read
Bicillin L-A Shortage: FDA's Lentocilin Importation and Billing Guidance
Pricing & Access· June 6, 2026 · 10 min read
GLP-1 pharmacy vs medical benefit: routing, cost-sharing, and PA impact
By Ran Chen#GLP-1#Pharmacy Benefit#Medical Benefit
Pricing & Access· May 22, 2026 · 9 min read
J-code timing and interim billing risk for new buy-and-bill biologics
By Ran Chen#Medicare Part B#HCPCS#J-Code